Objective  To evaluate the application effect of closed plasma reinfusion in the treatment of patients with double plasma molecular absorption system (DPMAS).   Methods  A total of 60 patients who underwent DPMAS treatment in our hospital from May 2021 to February 2023 were selected and randomly divided into three groups: non-reinfusion group, closed plasma reinfusion 400 ml group, and closed plasma reinfusion 600 ml group, with 20 patients in each group. The loss of albumin after the completion of DPMAS treatment and the change in bilirubin levels in the blood before and after plasma reinfusion in the closed plasma reinfusion groups were compared.  Results  After DPMAS treatment and reinfusion, the remaining albumin levels in different locations of the three groups were significantly different (bilirubin adsorber: 11.9(10.4, 13.0)g vs. 1.2 (1.0, 1.5)g vs. 0.8(0.6, 0.9)g, H=49.266, P<0.001). hemoperfusion device: 11.9 (10.4, 13.0) g vs. 4.0 (3.7, 5.2) g vs. 1.3(1.1, 2.0)g, H=52.477, P<0.001). extracorporeal circuit: 11.9(10.4,13.0)g vs. 9.0(7.9,10.0)g vs. 3.2(2.2, 3.8)g, H=46.787, P<0.001). The average albumin loss was also significantly different [11.9(10.4, 13.0)g vs. 4.7(4.3, 5.3)g vs. 1.8(1.4, 2.0)g, H=52.465, P<0.001]. In the closed plasma reinfusion groups (400 ml and 600 ml), no statistically significant difference was observed in bilirubin levels before [(236.21±98.31) vs. (224.07±64.63)mmol/L, t=-0.461, P=0.647] and after reinfusion [(233.83±99.98) vs. (220.04±66.67)mmol/L, t=-0.513, P=0.611].  Conclusion  Closed plasma reinfusion can not only reduce the loss of albumin in patients but also does not increase the risk of bilirubin shedding.